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Abstract
Background: Ultrasonography (US) studies carried out on joints of juvenile idiopathic arthritis (JIA) patients in
clinical remission demonstrate the presence of subclinical synovitis. The significance of subclinical synovitis and the
positive power Doppler (PD) signal on US in JIA in clinical remission is not well understood. The objectives of this
study were to assess whether the changes detected by US in patients with JIA in clinical remission can predict
disease flare and to evaluate factors associated with flare and joint damage over 30 months of follow-up.
Methods: A prospective study was performed with clinical and ultrasound evaluation in 34 joints of JIA patients in
clinical remission. Clinical evaluation including physical exam, functional capacity and inflammatory markers was
performed at baseline and every six months thereafter, for a total period of 30 months. US evaluation included
presence of synovitis, PD signal and erosion at baseline and every 12 months thereafter. Subclinical synovitis was
defined when there was synovitis with or without positive PD signal in US joints of patients in clinical remission.
Flare was defined as any joint presenting clinical arthritis requiring therapy modification.
Results: We evaluated a total of 35 patients, 28 (80%) girls, 14 (40%) persistent oligoarticular subtype, 12 (34.3%)
oligoarticular extended and 9 (25.7%) polyarticular and 26 (74.3%) in remission on medication. Twenty (57.1%)
patients flared. The risk of flare was five times higher in patients with positive PD signal and 14 times higher in
patients in remission on medication. Regarding the assessment of joints after 6 months and 12 months of US
evaluation, 70/3162 (2.2%) joints and 80/2108 (3.8%) joints flared, respectively. Joints with subclinical synovitis with
positive PD signal flared more after 6 and 12 months. Twenty five of 2108 (1.2%) joints showed erosion over time.
Joints with subclinical synovitis with or without positive PD signal showed more erosion.
Conclusions: Patients in remission on medication with subclinical synovitis with positive PD signal on US have a
higher risk of flare, therefore they should be monitored closely during treatment. In the same way, joints with
subclinical synovitis with or without positive PD signal should be monitored due to the risk of flare and joint
damage.
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Background
Juvenile idiopathic arthritis (JIA) is the most common
chronic rheumatic disease in childhood, causing disabil-
ity and reduced quality of life. It is a heterogeneous con-
dition, characterized by periods of activity and clinical
remission [1–4].
Joint ultrasonography (US) is a promising tool for
diagnostic, prognostic and treatment efficacy evaluation
in JIA patients. It can improve upon the physical exam-
ination by providing assessment of specific joints, such
as the hips, ankles, midfoot and wrists, it has the poten-
tial for early detection of synovitis and determination of
JIA activity and flare and it improves accuracy of steroid
placement in the joints for intra-articular injections [5–
12]. US studies carried out in joints of JIA patients in
clinical remission demonstrate the presence of subclin-
ical synovitis [5, 7, 13–20]. Subclinical synovitis detected
by US and magnetic resonance imaging (MRI) is com-
mon in adults with rheumatoid arthritis (RA) in clinical
remission and is associated with structural progression
and joint damage [21–25].
The significance of subclinical synovitis and the posi-
tive power Doppler (PD) signal on US in JIA in clinical
remission is not fully understood. Persistent ultrasound
abnormalities may reflect residual inflammatory activity
undetected by clinical and laboratory examinations, with
increased risk of disease flare and joint damage progres-
sion [7, 14, 16, 26]. Magni-Manzoni et al. evaluated the
ultrasonographic abnormalities in relapses of patients
with JIA in clinical remission and found that none of the
parameters were of prognostic value for patients with
JIA, contradicting the findings in adults. Different from
what is reported in RA, this study found that patients
with persistent inactive disease had a greater frequency
of PD signal than patients who flared. This shows that
further studies should be performed to assess the true
value of ultrasound changes – including the PD signal -
in relation to JIA activity and remission [17].
The objectives of this study were to evaluate whether
changes detected by US in patients with JIA in clinical
remission could predict disease flare or joint damage
(erosion) and to evaluate possible factors associated with
JIA flare and joint damage over 30 months of follow-up.
Methods
Population
A longitudinal study was carried out in our Pediatric
Rheumatology Unit. We evaluated JIA patients classified
according to the criteria of the International League of
Associations for Rheumatology (ILAR) [27, 28] and
considered in clinical remission by the Wallace’s criteria
[29, 30] from August 2010 to October 2013.
Inclusion criteria:
 Oligoarticular or polyarticular JIA
 Clinical remission
 Aged between 5 and 18 years
Exclusion criteria:
 Overlap with other autoimmune rheumatic diseases
 Deformity that could compromise the
ultrasonographic evaluations proposed by the study
 Other associated diseases that could compromise
the joint evaluation (e.g., diabetes mellitus,
hypothyroidism)
Clinical and laboratory evaluation
Patients were evaluated by an experienced pediatric
rheumatologist with more than 20 years of clinical
rheumatology practice (MTT), certified by the Pediatric
Rheumatology International Trials Organisation
(PRINTO) and who was blinded to the US findings, to
confirm the clinical remission and assess the progression
of the clinical and functional features. The following
were evaluated: current age, age of disease onset, disease
duration, disease subtype, type of clinical remission (on
and off medication) and time on clinical remission.
The following parameters were considered in the clin-
ical assessment:
 Active/limited joint count
 Assessment of functional capacity using the
Childhood Health Assessment Questionnaire
(CHAQ) [31]
 Physician’s global visual analog scale (VAS) (0–10)
 Parent or patient’s global VAS (0–10)
 Medications used: non-steroidal anti-inflammatory
drugs (NSAIDs), corticosteroids, disease-modifying
antirheumatic drugs (DMARDs) and biologics
 Need to introduce or increase the dose of therapy
Patients underwent laboratory tests, including
complete blood count, erythrocyte sedimentation rate
(ESR) (Ves-Matic; reference value: 0–20 mm3/h) and
C-reactive protein (CRP) (nephelometry and/or agglu-
tination; reference value: <0.8 mg/dL), as well as
ophthalmologic assessment to determine the absence
of active uveitis. The clinical, laboratory and ophthal-
mologic evaluations were performed at the beginning
of the study and every six months thereafter, for a
total period of 30 months for each patient.
Ultrasonographic evaluation
The ultrasonographic evaluation was performed by an
experienced musculoskeletal radiologist (SAVM), who
was blinded to the clinical variables, at the beginning of
the study and every 12 months thereafter. The estimated
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time for performing the exam in each child was 20 to
30 min. The gray scale and PD ultrasonographic evalu-
ation was performed using a MyLab™ 60 device (Esaote)
with a linear transducer with frequency between 6 and
18 Mega Hertz (MHz) for grayscale and up to 12.5 MHz
for PD. A pulse repetition frequency of 500–750 MHz
with a low-wall filter was used, and the gain was ad-
justed so that no signal was seen on the bone surface or
below it.
Seventeen joints were evaluated bilaterally: 2nd to 5th
metatarsophalangeal joints (MTPs), ankles, knees, hips,
elbows, wrists, 2nd to 5th metacarpophalangeal joints
(MCPs) and 2nd to 5th proximal interphalangeal joints
(PIPs) of the hands, according to the evaluation proce-
dures standardized by the European League Against
Rheumatism (EULAR) [32]. The recesses evaluated in
each joint were the following:
 2nd to 5th MTPs: dorsal longitudinal recess
 Ankles: tibiotalar: anterior longitudinal recess and
subtalar: medial longitudinal recess
 Knees: suprapatellar longitudinal recess
 Hips: anterior longitudinal recess
 Elbows: anterior and posterior longitudinal recesses
 Wrists: longitudinal dorsal radiocarpal and
midcarpal recesses and transverse dorsal distal
radioulnar recesses
 2nd to 5th MCPs: volar and dorsal longitudinal
recesses and radial longitudinal recess of the 2nd MCP
 2nd to 5th PIPs of the hands: volar and dorsal
longitudinal recesses
The following ultrasonographic parameters were eval-
uated, based on the Outcome Measures in Rheumatol-
ogy (OMERACT)/EULAR definitions [33, 34] (Fig. 1):
A. Synovitis: presence of joint effusion and/or synovial
hypertrophy - identified in each joint as an area of
hypoechoic or anechoic intra-articular material, com-
pressible and displaceable, with absence of PD signal
(joint effusion) or a hypoechoic area of non-displaceable
and poorly compressible material, with absence or pres-
ence of PD signal (synovial hypertrophy). A semi-
quantitative analysis was performed using a score
ranging from 0 to 3: 0 – no synovitis; 1 – minimal syno-
vitis in joint recess up to the joint capsule, but without
causing it to bulge; 2 – synovitis in the entire joint
recess causing bulging of the joint capsule, but without
extension to the bone diaphysis; and 3 – synovitis in
joint recess with bulging of the joint capsule and exten-
sion to at least one bone diaphysis (except for the tibio-
talar and subtalar joints). Grades 0 or 1 were considered
normal, and grades 2 or 3 were considered definitive
pathological changes [35].
B. Blood flow: defined by the presence of PD signal
performed only in areas where grade 1 to 3 joint syno-
vitis was detected. A qualitative score, which defined the
positive (any degree) or negative PD signal, was used
[35].
C. Bone erosion: intra-articular discontinuity of the
bone surface seen in two perpendicular planes. Bone
erosions were evaluated according to a semi-quantitative
scoring system: 0 – regular bone surface; 1 – irregular
bone surface without formation of defects seen in two
Fig. 1 Ultrasonographic parameters. Synovitis in the anterior elbow (a. Grade 1; b. Grade 2; c. Grade 3) and synovial flow in the radiocarpal wrist
(d. Positive power Doppler signal)
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planes; 2 – defect formation on the bone surface seen in
two planes; and 3 – bone defect creating extensive bone
destruction [35].
Subclinical synovitis was defined in the presence of
joint physical examination without arthritis and ultra-
sonographic examination with grade 2 or 3 synovitis
with or without positive PD signal. Erosion was de-
fined in the presence of grade 2 or 3 discontinuity of
the bone surfaces.
Information regarding assessment of inter-observer
and intra-observer reliability of ultrasound evaluation, as
well as the inclusion of a control group of healthy chil-
dren for comparison with the findings of JIA patients,
have been previously reported [19].
Clinical flare of JIA was considered as when any joint
exhibited swelling associated with pain, heat and/or limi-
tation on physical examination, requiring a re-
introduction or increase of DMARD or intra-articular
injection. Flare was assessed 6 and 12 months after each
ultrasonographic examination. Joint damage was evalu-
ated by the appearance of erosions in the ultrasound ex-
aminations performed at 12 and 24 months.
Categorical variables were analyzed using the chi-
squared and Fisher tests. Numerical variables were eval-
uated using the Mann-Whitney test. To assess the ef-
fects of possible factors on the time to flare, the Kaplan-
Meier and Cox survival analysis models were used. The
log rank test was used to compare categorical variables
between the patients who flared and patients who did
not over the period analyzed. Cox regression was used
to evaluate the effects of numerical variables or of mul-
tiple factors simultaneously on the time to flare. The
variables significant at 15% were included in the Cox re-
gression with multiple factors. A 5% significance level
was adopted for all statistical tests. The statistical pro-
grams SPSS 20.0 and STATA 12 were used.
Results
Demographic and clinical data
One hundred and eight patients with oligoarticular or
polyarticular JIA were regularly evaluated at the begin-
ning of the study, 44 were in clinical remission, on medi-
cation or off medication. Of these, four refused to
participate in the study, and four had associated comor-
bidities and were excluded. One patient withdrew from
the study after enrollment, and 35 patients were initially
evaluated. Thirty-five patients were re-evaluated at
6 months, 32 at 12 months, 30 at 18 and 24 months and
28 at the final 30-month follow-up, due to loss of follow
up and were not later scanned. Of the 35 patients at the
initial evaluation, 26 (74,3%) were in remission on medi-
cation, with a mean time on clinical remission of
1,42 years. No patient had positive rheumatoid factor.
The medication used were methotrexate (20 patients),
leflunomide (2 patients), cyclosporine (1 patient), metho-
trexate and biologic (1 patient) and hydroxicloroquine (2
patients). Nine patients were in remission off medica-
tion, with a mean remission time of 3 years. Demo-
graphic and clinical data from the initial evaluation of all
patients are shown in Table 1.
Of these 35 patients evaluated, 20 (57.1%) patients had
JIA flare during the evaluation period. There was no dif-
ference in clinical data and medication use between pa-
tients who flared and did not. Demographic and clinical
data from the initial evaluation of the patients who
flared and patients who did not during the study are
shown in Table 2.
Ultrasonographic data
Throughout the study, 24 (68.6%) patients had subclin-
ical synovitis (nine with positive PD signal), and 7 had
erosion in at least one joint. Subclinical synovitis with or
without positive PD signal was more frequent in patients
who were older at the initial evaluation (p = 0.047), older
at the onset of JIA (p = 0.036), female (p = 0.021), with
polyarticular involvement (p = 0.002) and shorter remis-
sion time (p = 0.022). There was no relationship between
subclinical synovitis and the JIA follow-up time, positive
antinuclear antibodies (ANA), previous uveitis, type of
remission, CHAQ score, physician’s or parents’ and
Table 1 Demographic and clinical data of all patients (n = 35)
at the initial evaluation
Mean age ± SD 11.6 ± 3.8 years
Mean age at JIA onset ± SD 4.4 ± 3.2 years
Mean time of JIA duration ± SD 7.1 ± 3.5 years
Females 28 (80%)
Subtype
Oligoarticular persistent 14 (40%)
Oligoarticular extended 12 (34.3%)
Polyarticulara 9 (25.7%)
ANA positive 20 (57.1%)
Previous uveitis 4 (11.4%)
Type of clinical remission
On medication 26 (74.3%)
Off medication 9 (25.7%)
Mean time on clinical remission ± SD 1.9 ± 2.2 years
CHAQ median (minimum – maximum) 0 (0–0.375)
Global physician’s VAS median (minimum – maximum)b 0 (0–1)
Global parents or patient’s VAS median (minimum – maximum) 0 (0–5)
ESR mm3/h (mean ± SD) 6.8 ± 4.9
CRP mg/dL (mean ± SD) 0.2 ± 0.15
SD standard deviation, JIA juvenile idiopathic arthritis, ANA antinuclear
antibody, ESR erythrocyte sedimentation rate, CRP C-reactive protein, CHAQ
Childhood Health Assessment Questionnaire, VAS visual analogue scale
aNo patient had positive rheumatoid factor. bOne patient received a Global
physician’s VAS of 1 due to joint limitation explained by previous joint damage
and not due to active disease at the time of evaluation
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patients’ VAS, ESR or CRP. Subclinical synovitis with
positive PD signal occurred in patients with shorter re-
mission time (p = 0.009). There was no association with
the other variables.
Clinical and ultrasonographic data per joint
Initially ninety-seven ultrasonographic evaluations were
performed, for a total of 3298 joints evaluated. Of these,
3162 joints were re-evaluated clinically after 6 months
and 2108 joints after 12 months. After 6 and 12 months,
70/3162 (2.2%) and 80/2108 (3.8%) of the joints flared,
respectively. The flare time after the ultrasonographic
evaluation ranged from 0,25 to 18 months, with a mean
of 5.95 months. The mean number of joints affected in
each flare episode during the study was one joint per
flare (range 1 to 16 joints), and the main joints affected
were the knees, ankles and wrists.
Throughout the follow-up, the main joints with sub-
clinical synovitis with or without positive PD signal were
the wrists (n = 21), ankles (n = 13), elbows (n = 13),
knees (n = 7) and small joints of hands and feet
(n = 15). The main joints with subclinical synovitis with
positive PD sign were the wrists (n = 7), knees (n = 6)
and elbows (n = 4).
Joints with subclinical synovitis with or without
positive PD signal flared more after 6 and 12 months
(Table 3).
A total of 2108 joints were evaluated for erosion, and
25 (1.2%) exhibited erosion after 12 months. The main
joints that presented erosion after 12 months were
MCFs (n = 12), wrists (n = 6) and hips (n = 3). Joints
with subclinical synovitis, with or without positive PD
signal, showed more erosion during the follow-up of the
disease (p < 0.001). There was no association between
erosion and the isolated positive PD signal (p = 1).
Possible factors associated with JIA flare over the 30-
month evaluation
In the Kaplan-Meier survival analysis for related categor-
ical variables, the survival functions were different for
patients on medication at the time of flare (p < 0.001).
For the other variables, there were no differences be-
tween groups (gender p = 0.56, JIA subtype p = 0.791,
antinuclear antibodies p = 0.403, subclinical synovitis
p = 0.694 and PD signal p = 0.104). The time leading up
to flare was shorter in patients on medication at the time
of flare and in patients with a subclinical synovitis with
positive PD signal. In the univariate Cox model for the
continuous variables, none of the variables was signifi-
cant for the JIA flare (age at onset, follow-up time, ESR
and CRP).
In the Cox regression with multiple factors, the pres-
ence of subclinical synovitis with positive PD signal
(p = 0.104) and the use of medication at the time of flare
Table 2 Demographic and clinical data from the initial evaluation of the patients who flared and did not during the study
Total patients (n = 35) Flare (n = 20) No flare (n = 15) p
Mean age ± SD (years) 11.5 ± 3.6 11.6 ± 4 0.856‡
Mean age at JIA onset ± SD (years) 3.8 ± 2.8 5.1 ± 3.5 0.298‡
Mean time of JIA duration ± SD (years) 7.6 ± 3.1 6.3 ± 4.1 0.202‡
Females 17 11 0.430a
Joint involvement 0.486†
Oligoarticular (Oligoarticular persistent) 7 7
Polyarticular (Oligoarticular extended + polyarticular) 13 (8 + 5) 8 (4 + 4)
ANA 12 8 0.693†
Previous uveitis 4 0 0.119a
Type of clinical remission 0.129a
On medication 17 9
Mean time on clinical remission ± SD 1.2 ± 0.5 years 2.6 ± 3.2 years 0.064‡
CHAQ median (min – max) 0 (0–0.375) 0 (0–0.375) 0.805‡
Global physician’s VAS median (min – max) 0 (0–1)b 0 (0) 0.805‡
Global parents or patient’s VAS median (min – max) 0 (0–4) 0 (0–5) 0.352‡
ESR mm3/h mean ± SD 7.5 ± 5.7 6 ± 3.5 0.587‡
CRP mg/dL mean ± SD 0.25 ± 0.15 0.23 ± 0.14 0.730‡
SD standard deviation, JIA juvenile idiopathic arthritis, ANA antinuclear antibody, ESR erythrocyte sedimentation rate, CRP C-reactive protein, CHAQ Childhood
Health Assessment Questionnaire, VAS visual analogue scale
aFisher’s test, † chi-squared test, ‡ Mann-Whitney test
bOne patient received a Global physician’s VAS of 1 due to joint limitation explained by previous joint damage and not due to active disease at the time
of evaluation
Miotto e Silva et al. Pediatric Rheumatology  (2017) 15:80 Page 5 of 9
(p < 0.001) were included, and both the subclinical syno-
vitis with positive PD signal (p = 0.046) and the use of
medication (p < 0.001) were significant. The risk of flare
in patients with subclinical synovitis with positive PD
signal was five times higher than in patients with sub-
clinical synovitis without positive PD signal on US (haz-
ard ratio (HR) = 5.07, 95% confidence interval
(CI) = 1.03 to 24.93). Patients in remission on medica-
tion at the time of flare showed a risk of flare 14 times
higher than patients off medication (HR = 14.16, 95%
CI = 3.22 to 62.31). Figure 2 shows the survival function
(no flare) for the four groups resulting from the combin-
ation of subclinical synovitis with positive PD signal and
use of medication.
Discussion
In this study, we evaluated whether ultrasonographic
changes in patients with JIA in remission can predict
flare and the factors associated with the flare. The sub-
clinical synovitis detected by US was not a predictor of
flare; however, subclinical synovitis with positive PD sig-
nal separately and remission on medication determined
an increased risk of JIA flare. The joints with subclinical
synovitis with or without positive PD signal flared more
over 12 months, and the joints with subclinical synovitis
also showed more erosion during the disease follow-up.
Subclinical synovitis with or without positive PD oc-
curred in approximately two-thirds of the patients dur-
ing the study, being more frequent in females, in
patients with polyarticular involvement, who were older
at the initial evaluation, who were older at the JIA onset
and in patients with shorter remission time. The sub-
clinical synovitis with positive PD signal occurred in pa-
tients with shorter remission time. Data from the
literature showed a higher frequency of flare in patients
with older age at onset, with polyarticular involvement
and under methotrexate at the time of evaluation [19].
Over 50% of patients flared during the study period,
with no difference in demographic and clinical data be-
tween those who flared and those who did not. A study
by Magni-Manzoni et al. carried out in patients with JIA
in clinical remission found that the patients with persist-
ently inactive disease were younger at disease onset and
at the beginning of the study and were more likely to
have a positive PD signal than those who flared [17]. In
contrast, we observed that joints with subclinical syno-
vitis with or without positive PD signal flared statistically
more after 6 and 12 months. A retrospective study by
Nielsen et al. showed that in 62 patients with recently
diagnosed JIA, the joints with subclinical synovitis had a
29% probability of developing clinical arthritis 6 months
after the initial evaluation with US [36].
Subclinical synovitis with or without positive PD was
not a predictor of disease flare in our study. Janow et al.
evaluated the knees and ankles of patients with JIA using
PD US. Of the patients with subclinical synovitis, 21.4%
developed active disease within six months [8]. Subclin-
ical synovitis without positive PD signal may not have
been related to disease flare in our study because many
of these changes may be residual in the joint, not char-
acterizing subclinical activity. On the other hand, the
subclinical synovitis with positive PD signal, indicating
hypervascularization of the synovial tissue, is a more
specific parameter of joint activity [17, 37–39]. We can
also conclude that the most suitable definition for sub-
clinical synovitis must consider the positive PD signal
because it was the main predictor of JIA flare.
In patients with RA, the positive PD signal predicts
short-term flare after clinical remission and is the major
predictor of erosive damage [24, 37]. In our study, there
was no association between the positive PD signal and
the onset of erosions; the joints with subclinical synovitis
(with or without positive PD) showed more erosion dur-
ing the disease. The mechanism and site of onset of ero-
sions in children are different from those of adults,
which may explain the different findings of the RA stud-
ies [36, 40, 41].
The study by Magni-Manzoni et al. prospectively eval-
uated the predictive power of ultrasonographic abnor-
malities (joint effusion, synovial hypertrophy and
positive PD signal) in the relapses of patients with JIA in
clinical remission. Of the 39 patients, 38.5% flared, and
61.5% remained in remission, but none of the parame-
ters evaluated had prognostic value for the patients. In
this study, the patients with persistent inactive disease
had a greater frequency of PD signal than patients who
flared and the authors suggested that the low grade of
the positive PD signal (most joints were positive grade 1
may be the cause of this finding. In addition, patients
with sustained remission, who had a greater prevalence
Table 3 Ultrasonographic data of joints and association with flare after 6 and 12 months of evaluation
Flare after 6 months
(n = 70)
No flare after 6 months
(n = 3092)
p Flare after 12 months
(n = 80)
No flare after 12 months
(n = 2028)
p
Subclinical synovitis with positive
PD signal
5 (7.1%) 14 (0.5%) <0.001a 4 (5%) 10 (0.5%) 0.001a
Subclinical synovitis with or
without positive PD signal
10 (14.3%) 59 (1.9%) <0.001a 8 (10%) 45 (2.2%) 0.001a
PD power Doppler
a Fisher’s test
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of positive PD signal, were younger than patients with
synovitis flare [17]. In our study, the positive PD signal,
regardless of grade, determined a higher risk of JIA flare,
corroborating with the findings of studies on RA [21–
25, 42]. In addition, contrary to the findings of Magni-
Manzoni et al., in our study all patients – except one
who was 7.5 years old – with a positive PD sign were ad-
olescents with a mean age at the beginning of the study
of 12.6 years (range 7.5 years to 15.9 years), which
strengthens the fact that our findings related to the posi-
tive power Doppler signal were actually related to in-
creased synovial blood flow by subclinical disease
activity rather than normal intra-articular flow.
Our study also found that the use of medication dur-
ing clinical remission determined a higher risk of JIA
flare. Collado et al. found more ultrasonographic
changes in patients with inactive JIA on medication, al-
though the difference was not statistically significant
[20]. This finding suggests that patients who are in clin-
ical remission and still on medication have low disease
activity but not actual inactivity, which places them at
higher risk for disease flare.
This study has some limitations. The number of JIA
patients evaluated was small. Also, there was only one
pediatric rheumatologist who examined all patients and
It would have increased the strength of the study to have
had a different evaluator for the clinical evaluation.
However, we believe that the extensive experience of our
evaluator has been more than sufficient to reduce the
evaluation biases that could have occurred. Due to the
absence of ultrasonographic standards for children at
the time the study was performed, we used criteria de-
fined for adults, which may have affected the
interpretation of the results. The OMERACT group re-
cently defined the criteria for joint assessment by US in
healthy children and defined the pathological changes in
children’s joints [41, 43]. Collado et al. recently systema-
tized the US examination of knee, ankle, wrist and 2nd
MCP joints in healthy children of different age groups,
leading to the publication of an atlas, including the PD
signal findings. In that study, the standardization of the
ultrasonographic examination was similar to our
method. Furthermore, that study demonstrated that the
positive PD signal in the synovial recesses does not
occur in healthy children, which reinforces the import-
ance of our results regarding the positive PD signal [44].
A recent study by Lanni et al. found that the lateral re-
cess of the subtalar joint may present more synovitis on
US than the medial recess [45]. Unfortunately, in our
study, we evaluated only the medial recess of this joint.
The ultrasonographic findings were not compared with
MRI, which is the current gold standard for joint evalu-
ation. Nevertheless, a study of 59 children with JIA
showed that ultrasonographic evaluation of the joints
may be comparable to MRI findings [46].
Our study is the first to describe the subclinical syno-
vitis with positive PD signal as a predictor of flare in JIA
patients in clinical remission. The current criteria for
clinical remission do not include evaluation by imaging,
and more studies related to subclinical synovitis with
positive PD signal can provide valuable information to
optimize the treatment and follow-up of JIA patients.
Conclusions
Subclinical synovitis with positive PD signal and clinical
remission on medication increased risk of JIA flare.
Fig. 2 Cox survival function (no flare) for the groups resulting from the combination of PD signal levels and use of medication. PD –
power Doppler
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Joints that had subclinical synovitis with or without posi-
tive PD signal flared more over 12 months. The joints with
subclinical synovitis with or without positive PD signal
also showed more erosion during disease follow-up. Pa-
tients in clinical remission on medication and subclinical
synovitis with positive PD signal on US should have the
medication withdrawal delayed due to the risk of JIA flare.
Joints with subclinical synovitis with or without positive
PD signal should be monitored more frequently due to
the risk of flare and long-term joint damage.
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